Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel.
Itay Lotan,Itay Lotan,Adi Wilf-Yarkoni,Adi Wilf-Yarkoni,Yitzhak Friedman,Yitzhak Friedman,Hadas Stiebel-Kalish,Hadas Stiebel-Kalish,Israel Steiner,Israel Steiner,Mark A. Hellmann,Mark A. Hellmann +11 more
Reads0
Chats0
TLDR
In this paper, the authors report real-life safety data of the BNT162b2 COVID-19 vaccine in a cohort of MS patients, and an anonymous survey was distributed to 425 MS patients.Abstract:
Background and purpose Although the COVID-19 vaccines are currently recommended for people with multiple sclerosis (MS), the fact that they were not specifically tested in people with MS raises uncertainty regarding their safety in this population. The purpose of this study was to report real-life safety data of the BNT162b2 COVID-19 vaccine in a cohort of MS patients. Methods An anonymous survey was distributed to 425 MS patients. Participants were asked general demographic and disease-related questions and specific questions regarding the safety profile of the COVID-19 vaccine. Results Of the 425 MS patients, 262 completed the questionnaire. The median (range) participant age was 42 (22-79) years, 199 participants were women (75.9%), and 66 participants (25.2%) had associated comorbidities. A total of 198 participants (75.6%) were treated with disease-modifying therapies. In all, 239 participants (91.2% of the responders) had received the BNT162b2 COVID-19 vaccine. Of these, 182 (76.1%) were aged 55 years. Adverse events were reported by 136 participants (56.9%; 52.5% of those aged 55 years; p = 0.1517) and 36 participants (15.1%) reported new or worsening neurological symptoms following the vaccination, the most frequent being sensory disturbances (21 participants, 58.3%). Most symptoms occurred within the first 24 h after vaccination and resolved within 3 days. A total of 28 participants (77.8%) did not require any medication to treat their symptoms. Conclusions This survey indicates an overall favorable safety profile of the BNT162b2 vaccine in people with MS. These data should be confirmed in further prospective, large-scale studies.read more
Citations
More filters
Journal ArticleDOI
COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose
Sapir Dreyer-Alster,Shay Menascu,Mathilda Mandel,Emanuel Shirbint,David Magalashvili,Mark Doyle,Shlomo Flechter,Uri Givon,Diana Guber,Yael Stern,Shmuel Miron,Michael Polliack,Rina Falb,Polina Sonis,Michael Gurevich,Anat Achiron +15 more
TL;DR: In this paper , the authors assessed the safety of the third dose of the BNT162b2-COVID-19 mRNA vaccination in adult MS patients and evaluated SARS-CoV-2 IgG response.
Journal ArticleDOI
Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis
Matteo Castaldo,Marta Waliszewska-Prosół,Maria Koutsokera,Micaela Robotti,M Straburzynski,Loukia Apostolakopoulou,Mariarita Capizzi,O. Çibuku,Fidel Dominique Festin Ambat,Ilaria Frattale,Z. Gadzhieva,Erica Gallo,Anna Gryglas-Dworak,G. Halili,A. A. Jusupova,Yana Koperskaya,Alo-Rainer Leheste,M. L. Manzo,Andrea Marcinnò,Antonio Marino,Petr Mikulenka,Bee Eng Ong,Burcu Polat,Zvonimir Popović,Eduardo Rivera-Mancilla,Adina Roceanu,Eleonora Rollo,Marina Romozzi,Claudia Ruscitto,Fabrizio Scotto di Clemente,Sebastian Strauß,Valentina Taranta,Maria Terhart,Iryna Tychenko,Simone Vigneri,Błażej Misiak,Paolo Martelletti,Alberto Raggi +37 more
TL;DR: In this paper , the authors found that vaccines are associated with a two-fold risk of developing headache within 7 days from injection, and the lack of difference between vaccine types enable to hypothesize that headache is secondary to systemic immunological reaction than to a vaccine-type specific reaction.
Journal ArticleDOI
Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started?
Gianmarco Bellucci,Virginia Rinaldi,Maria Chiara Buscarinu,Roberta Reniè,Rachele Bigi,Giulia Pellicciari,Emanuele Morena,Carmela Romano,Antonio Marrone,Rosella Mechelli,Marco Salvetti,Giovanni Ristori +11 more
TL;DR: In this article, the authors look over 18 months of the SARS-CoV-2 pandemic from the perspective of MS, dissect neuroinflammatory and demyelinating mechanisms associated with COVID-19, summarize pathophysiological crossroads between MS and SARS CoV2 infection, and discuss present evidence on COVID19 and its vaccination in people with MS.
Journal ArticleDOI
Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies.
Fioravante Capone,Matteo Lucchini,Matteo Lucchini,Elisabetta Ferraro,Assunta Bianco,Assunta Bianco,Mariagrazia Rossi,Alessandra Cicia,Alessandra Cicia,Antonio Cortese,Alessandro Cruciani,Valeria De Arcangelis,Laura De Giglio,Francesco Motolese,Biagio Sancetta,Massimiliano Mirabella,Massimiliano Mirabella,Vincenzo Di Lazzaro +17 more
TL;DR: In this paper, the authors evaluated the immunogenicity and safety of mRNA COVID-19 vaccines in a convenience sample of 140 MS patients treated with different DMTs, undergoing vaccination between April and June 2021.
Journal ArticleDOI
New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19
TL;DR: In this article , the authors report on nine patients (eight cases of MS and one case of NMOSD) who presented a disease relapse in close temporal association with their first AZD1222 vaccination dose against COVID-19.
References
More filters
Journal ArticleDOI
COVID-19 vaccination willingness among people with multiple sclerosis
TL;DR: In this article, the authors investigated the factors contributing to the willingness to receive COVID-19 vaccination in adults with multiple sclerosis (MS) and found that the vaccine willingness was positively associated with the risk of developing MS.
Journal ArticleDOI
Reactogenicity in the elderly of nine commercial influenza vaccines: results from the Italian SVEVA study
Stefania Spila-Alegiani,Stefania Salmaso,Maria Cristina Rota,Alberto Eugenio Tozzi,Roberto Raschetti +4 more
TL;DR: A 10-fold increase of reported adverse events following influenza vaccination in the 1995-1996 campaign was reported and the odds ratios, adjusted through a multivariate logistic model, were highest for whole vaccine recipients.
Journal ArticleDOI
SARS-CoV-2 vaccine candidates in rapid development.
TL;DR: Research regarding basic knowledge on the virus, updates on the animal models, current landscape of vaccines in clinical evaluation and updated research results on vaccine development are described.
Journal ArticleDOI
Causal relationship between immunological responses and adverse reactions following vaccination.
TL;DR: The pathogenicity of adverse reactions was investigated for anaphylactic reactions, systemic and local reactions following vaccinations, and initial innate immune responses are essential for the development of acquired immunity and are related to adverse events from different viewpoints.
Journal ArticleDOI
Incidence and Impact of COVID-19 in MS: A Survey From a Barcelona MS Unit.
Maria Sepúlveda,Sara Llufriu,Eugenia Martinez-Hernandez,Martí Català,Montse Artola,Ana Hernando,Carmen Montejo,Irene Pulido-Valdeolivas,Eloy Martinez-Heras,Mar Guasp,Elisabeth Solana,Laura Llansó,Domingo Escudero,Marta Aldea,Clara Prats,Francesc Graus,Yolanda Blanco,Albert Saiz +17 more
TL;DR: In this article, the authors investigated the incidence of coronavirus disease 2019 (COVID-19) in a single-center cohort of patients with MS and explored the contribution of their comorbidities and therapies to the outcome.
Related Papers (5)
Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register.
Nikos Evangelou,Afagh Garjani,Roshan dasNair,Rachael Hunter,Katherine A Tuite-Dalton,Elaine M Craig,W. J. Rodgers,Alasdair Coles,Ruth Dobson,Martin Duddy,David V. Ford,Stella Hughes,Owen R Pearson,Linda A Middleton,David Rog,Emma C. Tallantyre,Tim Friede,Rodden M. Middleton,Richard Nicholas +18 more